MatthewStevenDietzDOMSEd

Pediatric Hematology & Oncology • Salt Lake City, UT

Physician

Join to view full profile

Dr. Dietz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dietz's full profile

Already have an account?

Office
100 North Mario Capecchi Drive
Salt Lake City, UT 84113
Phone+1 801-662-4700

Education & Training

Oregon Health & Science University (OHSU Health)Residency, Pediatrics, 2013 - 2016
University of New England College of Osteopathic MedicineClass of 2013

Certifications & Licensure

UT State License 2020 - 2026
OR State License 2016 - 2023
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) Start of enrollment: 2020 Dec 31
Active, not recruiting
Phase 2
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT Start of enrollment: 2020 Oct 19
Recruiting
Phase 2
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Start of enrollment: 2021 May 03
Active, not recruiting
Phase 2
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Start of enrollment: 2020 Oct 13
Active, not recruiting
Phase 2
A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery Start of enrollment: 2020 Oct 07
Active, not recruiting
Phase 2
A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue Start of enrollment: 2022 Nov 14
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

13 citations
Integrated functional and mass spectrometry-based flow cytometric phenotyping to describe the immune microenvironment in acute myeloid leukemia.
Adam J. Lamble, Matthew S. Dietz, Ted Laderas, Shannon K. McWeeney, Evan F. Lind
Journal of Immunological Methods. 2017-11-23
5 citations
Measure Twice: Promise of Liquid Biopsy in Pediatric High-Grade Gliomas.
Matthew S. Dietz, Catherine Z. Beach, Ramon F. Barajas, Michael S. Parappilly, Sidharth K. Sengupta
Advances in Radiation Oncology. 2020-01-28
32 citations
Relevance of circulating hybrid cells as a non-invasive biomarker for myriad solid tumors
Matthew S. Dietz, Thomas L. Sutton, Brett S. Walker, Charles E. Gast, Luai Zarour
Scientific Reports. 2021-07-01